Why Partner?

After decades of unfulfilled potential, the commercial reality of gene therapies is rapidly taking shape. However, the leading drug developer organizations are repeatedly telling us that developing effective bioanalytical strategies to measure and predict immune response is a major bottleneck for them. We have learnt they have little visibility into which contract service providers and technology providers have the experience and expertise to meet their demands.

Last year we gathered 120+ industry representatives. At this year’s 3rd Annual Gene Therapy Immunogenicity Summit, we are set to unite 160+ clinical, pre-clinical, immunology, pharmacology, bioanalytical and toxicology leaders from the fields leading companies in person for the first time! Extensive research with these organisations found they are all actively seeking to collaborate with organizations that can help them solve their bioanalytical challenges holding back progress to market.

If you are a contract service provider with the bioanalytical experience and specific technologies to meet this exploding markets’ demands, then this conference will provide a platform for you to showcase your solutions to a niche audience of immunogenicity experts from the leading gene therapy developers.

We have a limited number of partnership opportunities available, including speaking positions across our agenda. From developing robust immunogenicity assays and companion diagnostics to providing novel in-vivo animal models for immune profiling, if you provide such services that would benefit our industry audience, then this meeting will provide a unique platform to showcase your solutions, generate new business leads, and source opportunities for partnerships.